AI brief of an SEC Form 8-K · CareDx, Inc. (CDNA)

CareDx Q2 revenue rises 52% to $132 million; raises 2026 revenue and EBITDA guidance

Positive Impact 4 of 5 earnings Written later

CareDx reported second-quarter 2026 revenue of $132 million, up 52% from a year earlier, and GAAP net income of $111 million, which includes a $113 million gain on the sale of its Lab Products business. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and its adjusted EBITDA guidance to $66 million to $78 million.

Key points

Revenue of $132 million versus $87 million in Q2 2025; Testing Services revenue rose 61% to $100 million.
GAAP diluted net income per share was $2.07, versus a loss of $0.16; non-GAAP diluted net income per share was $0.37, versus $0.10.
Adjusted EBITDA was $25 million versus $5 million in Q2 2025.
2026 guidance raised: revenue to $490 million to $500 million (from $447 million to $465 million) and adjusted EBITDA to $66 million to $78 million (from $43 million to $57 million).

The filing

CompanyCareDx, Inc. (CDNA)

Form8-K, current report

Filed with the SECJul 30, 2026, 4:03 PM ET

Accession number0001217234-26-000045

Items reported: 2.02 Results of Operations 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.